Florence Muchai

Author
Florence Muchai

Florence Muchai

Author

Florence is a writer with four years of experience specializing in Crypto, Finance and Tech. She graduated from Masinde Muliro University of Science and Technology (MMUST) where she studied Disaster Management and International Diplomacy. She also has a Master’s Degree in Clinical Psychology. She has worked as a freelance journalist, and at Cryptopolitan as a writer.


Author’s Articles

  • BlackRock goes into the deep for Bitcoin with a new BTC definition 

  • Crypto craze sweeps Europe! Binance survey reveals sky-high confidence among residents

  • Musk claims audits show less antisemitism on X than other social media apps

  • Bitcoin’s price dips to $40K – What’s next for crypto investors?

  • Binance vs. SEC: Oral arguments begin in landmark crypto legal battle

  • Zelenskiy expects further Western defense help for Ukraine in 2 months – Will crypto help?

  • Experts warn: The window for easy bond profits is closing

  • Binance’s market share plummets after CZ’s exit – The numbers don’t lie!

  • Bitcoin ETF vs buying BTC directly: Navigating the investment landscape

  • El Salvador’s Bitcoin love story takes a nosedive! Survey shows a 12% adoption setback

  • Crypto markets’ growth in 2023 -The numbers as per CoinGecko

  • The Crypto Weekend – What’s happening as BTC falls under $42K

  • Will Bitcoin weather the storm as Bank of Japan, ECB, and US inflation take center stage?

  • Can Gold and Bitcoin beat the odds amid rate cut skepticism?

  • Bitcoin’s performance is worrying amid S&P 500 major comeback

  • 5 things to know in crypto this week – Bitcoin ETFs, the SEC, and tons of disappointment

  • Crypto market today – Bitcoin sinks below $42K

  • JPMorgan CEO Jamie Dimon’s Pay Soars to $36 Million in 2023

  • Robinhood’s $7.5M settlement – The gamification scandal deep dive

  • China’s crypto space thrives in laundromats and cafes despite the ban 

  • Trump vs. Biden – Which Commander-in-Chief will ignite the crypto revolution?

  • Former Pfizer employee goes down for insider trading in COVID drug trial